Oncotarget

Research Papers:

Elevated CXCL1 increases hepatocellular carcinoma aggressiveness and is inhibited by miRNA-200a

Xiao Cui, Zhao Li, Jie Gao, Peng-Ji Gao, Yan-bing Ni and Ji-Ye Zhu _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:65052-65066. https://doi.org/10.18632/oncotarget.11350

Metrics: PDF 906 views  |   HTML 1787 views  |   ?  


Abstract

Xiao Cui1,2,*, Zhao Li1,*, Jie Gao1, Peng-Ji Gao1, Yan-bing Ni1, Ji-Ye Zhu1

1Department of Hepatobilliary Surgery, Beijing Key Surgical Basic Research Laboratory of Liver Cirrhosis and Liver Cancer, Peking University People's Hospital, Beijing 100044, China

2Department of General Surgery, The Second Hospital of Anhui Medical University, Hefei 230601, China

*These authors contributed equally to this work

Correspondence to:

Ji-Ye Zhu, email: zhujiye_bmu@163.com

Keywords: CXCL1, carcinogenesis, hepatocellular carcinoma, miR-200a

Received: May 26, 2016     Accepted: August 09, 2016     Published: August 17, 2016

ABSTRACT

In this study, we investigated the value of measurement of the chemokine CXCL1 in clinical management of hepatocellular carcinoma (HCC) and its possible role in the molecular pathogenesis of HCC. High CXCL1 expression predicted recurrence in HCC patients and promoted tumor progression in both in vivo and in vitro experimental systems. Overexpression of CXCL1 increased mitochondrial metabolism and activated the epithelial-to-mesenchymal transition (EMT). Using computational analysis we identified the microRNA miR-200a as a putative post-transcriptional regulator of CXCL1. We found that levels of miR-200a were inversely correlated with CXCL1 expression in HCC patient tissue samples by northern blot and qRT-PCR. Furthermore, CXCL1 was identified as a direct target which was bound and inhibited by miR- 200a. These findings provide new insights into the role of CXCL1 in HCC and its post-transcriptional regulation and suggest it may be a prognostic indicator for poor outcomes and a potential target for therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11350